QIAGEN N.V. (QGEN) 40.9 -0.06 (-0.15%)
40.9 -0.06 (-0.15%)
NL0012169213 - Common Stock - Premarket: 40.98 +0.08 (+0.2%)
Fundamental Rating
We assign a fundamental rating of 4 out of 10 to QGEN. QGEN was compared to 65 industry peers in the Life Sciences Tools & Services industry. Both the profitability and the financial health of QGEN get a neutral evaluation. Nothing too spectacular is happening here. QGEN has a valuation in line with the averages, but on the other hand it scores bad on growth
Profitability
Profitability Rating
QGEN's Return On Assets of 8.36% is amongst the best returns of the industry. QGEN outperforms 85% of its industry peers. The industry average Return On Assets is -8.19%.
QGEN has a Profit Margin of 22.75%. This is amongst the best returns in the industry. The industry average is -26.73%. QGEN outperforms 90% of its industry peers.
QGEN's Return On Equity of 15.67% is in line with the rest of the industry. The industry average Return On Equity is 16.52%.
QGEN has a Piotroski-F score of 6.00. This indicates an average health and profitability for QGEN.
VS Industry
ROA (8.36%) VS Industry: 85% outperformed.
-620.54
60.83
ROE (15.67%) VS Industry: 41% outperformed.
0.13
11,300.33
Profit Margin (22.75%) VS Industry: 90% outperformed.
-90,995.02
243.05
Valuation
Valuation Rating
QGEN's Price/Earning Ratio is a bit cheaper than the industry average which is at 24.54.
QGEN's low PEG Ratio, which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
Compared to an average industry Enterprise Value to EBITDA ratio of 16.32, QGEN is valued rather cheaply
The Price/Earnings Ratio is 15.55, which indicates a correct valuation of QGEN.
With a Forward Price/Earnings Ratio of 18.23, QGEN is valued rather expensively.
When comparing the current price to the book value of QGEN, we can conclude it is valued correctly. It is trading at 2.83 times its book value.
When comparing the price book ratio of QGEN to the average industry price book ratio of 2.30, QGEN is valued more expensive than its industry peers.
VS Industry
Price/Earnings (15.55) VS Industry: 75% outperformed.
385.00
7.69
Price/Book (2.83) VS Industry: 38% outperformed.
3,422.42
0.33
Enterprise Value/ EBITDA (11.57) VS Industry: 66% outperformed.
619.59
0.29
Growth
Growth Rating
QGEN shows quite a strong growth in Earnings Per Share. Measured over the last 5 years, the EPS has been growing by 18.43% yearly.
Measured over the past 5 years, QGEN shows a quite strong growth in Revenue. The Revenue has been growing by 10.97% on average per year.
QGEN shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 1.54%.
Based on estimates for the next 5 years, QGEN will show a decrease in Earnings Per Share. The EPS will decrease by -0.08% on average per year.
QGEN shows a small growth in Revenue. In the last year, the Revenue has grown by 3.27%.
QGEN is expected to show a small growth in Revenue. In the coming 5 years, the Revenue will grow by 1.76% yearly.
The EPS growth is decreasing: in the next 5 years the growth will be less than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming 5 years, we see that the growth is decreasing.
| Past | Future | ||||||
|---|---|---|---|---|---|---|---|
| 5Y | 3Y | 1Y | 1Y | 2Y | 3Y | 5Y | |
| EPS | 18.43% | 25.52% | 1.54% | -14.99% | -7.99% | -2.45% | -0.08% |
| Revenue | 10.97% | 14.45% | 3.27% | -2.56% | -1.04% | 1.35% | 1.76% |
Health
Health Rating
A Current Ratio of 2.23 indicates that QGEN has no problem at all paying its short term obligations.
An Altman-Z score of 3.35 indicates that QGEN is not in any danger for bankruptcy at the moment.
QGEN has a Quick Ratio of 1.89. This is a normal value and indicates that QGEN is financially healthy and should not expect problems in meeting its short term obligations.
The Altman-Z score is in line with the industry averages, which is at 2.19.
The Piotroski-F score of QGEN is 6.00. This is a neutral score and indicates average health and profitability for QGEN.
When comparing the Current Ratio of QGEN to the average industry Current Ratio of 4.84, QGEN is less able to pay its short term obligations than its industry peers.
Compared to an average industry Quick Ratio of 4.19, QGEN is worse placed to pay its short term obligations than its industry peers.
When comparing the Debt to Equity Ratio of QGEN to the average industry Debt to Equity Ratio of 0.09, QGEN required more debt to finance its operations than its industry peers.
VS Industry
Debt/Equity (0.45) VS Industry: 32% outperformed.
250.82
0.00
Quick Ratio (1.89) VS Industry: 35% outperformed.
0.23
49.75
Current Ratio (2.23) VS Industry: 31% outperformed.
0.23
49.75
Altman-Z (3.35) VS Industry: 60% outperformed.
-130.46
15.29
Dividend
Dividend Rating
QGEN does not give a dividend.
QIAGEN N.V.40.9
NYSE:QGEN (9/27/2022, 7:10:51 PM)-0.06 (-0.15%)
| GICS Sector | Health Care | ||
| GICS IndustryGroup | Pharmaceuticals, Biotechnology & Life Sciences | ||
| GICS Industry | Life Sciences Tools & Services | ||
| Earnings (Last) | 07-28 2022-07-28/bmo | Earnings (Next) | 11-01 2022-11-01 |
| Ins Owners | N/A | Inst Owners | 58.26% |
| Market Cap | 9.29B | Analysts | 74 |
| PE | 15.55 | Fwd PE | 18.23 |
| PEG (NY) | N/A | PEG (5Y) | 0.84 |
| P/S | 4.11 | P/B | 2.83 |
| EV/EBITDA | 11.57 | ||
| Dividend Yield | N/A | Dividend Growth | N/A |
| DP | N/A | Ex-Date | N/A |
| EPS 1Y | 1.54% | EPS 3Y | 25.52% |
| EPS 5Y | 18.43% | EPS growth Q2Q | -23.88% |
| EPS Next Y | -14.99% | EPS Next 2Y | -7.99% |
| EPS Next 3Y | -2.45% | EPS Next 5Y | -0.08% |
| Revenue growth 1Y | 3.27% | Revenue growth 3Y | 14.45% |
| Revenue growth 5Y | 10.97% | Revenue growth Q2Q | -9.13% |
| Revenue Next Year | -2.56% | Revenue Next 2Y | -1.04% |
| Revenue Next 3Y | 1.35% | Revenue Next 5Y | 1.76% |
| Current Ratio | 2.23 | Quick Ratio | 1.89 |
| Altman-Z | 3.35 | F-Score | 6 |
| Debt/Equity | 0.45 | ||
| ROA | 8.36% | ROE | 15.67% |
| ROIC | 23.84% | ROICg | 10.36% |
| PM | 22.75 | OM | 29.06 |
| Asset Turnover | 0.37 | ||
Fundamental Stock Screener Links
Fundamental Stock Screener
Find stocks with similar Fundamental rating on the USA
Best Fundamental Competitors Stock Screener
Find the competitors with the best fundamentals on the USA
Best Valuation Competitors Stock Screener
Find the competitors with the best valuation on the USA
Best Dividend Competitors Stock Screener
Find the competitors with the best dividend on the USA